Vascular Device Sales Rise as Profits Fall

Device makers and distributors should note that LeMaitre's expenses grew faster than its revenue this quarter.

Updated on Nov. 4, 2026 in Corporate Finance

Vascular Device Sales Rise as Profits Fall

LeMaitre Vascular, a Burlington, Massachusetts maker of vascular surgery devices, reported third-quarter 2026 net sales of $68.0 million, up 11% from a year earlier, while operating income fell 13% to $17.7 million. The company also bought certain vascular assets from B. Braun for $19.2 million in October.

Why it matters

For operators in medical device manufacturing and distribution, the quarter shows revenue growth outpacing profit growth, as operating expenses rose 21% year over year. The acquisition and the company's cash position of $390 million signal how a mid-sized device maker is deploying capital to expand its product lines.

LeMaitre reported Q3 2026 net sales of $68.0 million, up 11% year over year, with headcount of 678 up 7% from a year earlier. Cash and short-term marketable securities totaled $390 million at September 30, 2026, while the B. Braun acquisition price was $19.2 million against $9.4 million in 2025 sales of the acquired products.

The players

LeMaitre Vascular, Inc.

A Burlington, Massachusetts maker of vascular surgery devices, including the Artegraft graft line, with sales across the Americas, EMEA and APAC.

B. Braun

A German medical device and pharmaceutical company whose vascular asset sale to LeMaitre was valued at $19.2 million.

The details

Operating expenses grew 18% against adjusted prior-year figures, which the company attributed to belt-tightening in Q3 2025, while gross margin rose 90 basis points on higher average selling prices and operational efficiencies. Artegraft sales increased 18% in the quarter, with grafts and shunts driving much of the growth. Full-year 2026 net sales are guided to $274.8 million to $276.8 million and full-year EPS to $2.77 to $2.82.

September 30, 2026: Quarter end and balance sheet date for reported figures.
October 2026: Acquisition of certain B. Braun vascular assets closed for $19.2 million.
October 27, 2026: Board approved a quarterly dividend of $0.25 per share.
November 4, 2026: Q3 2026 results released and conference call held.
December 3, 2026: Quarterly dividend payment date.

Market Landscape

LeMaitre's 18% Artegraft growth and expansion through the B. Braun asset purchase follow a pattern of acquiring adjacent vascular products rather than building them internally. The quarter's gross margin of 71.7% sits well above the operating margin, which reflects the company's continuing spending on commercial expansion.

Operators in device distribution and manufacturing should weigh the gap between revenue growth and operating income, since rising operating expenses absorbed much of the sales gains this quarter. Those tracking supplier consolidation may view the B. Braun asset transfer as a signal that vascular product lines are changing hands.

The takeaway

Watch whether LeMaitre's expenses moderate in coming quarters, since the company's full-year EPS guidance of $2.77 to $2.82 depends on margin discipline. Businesses that buy or sell vascular products should track how the acquired B. Braun lines perform against the company's stated break-even expectation for the next quarter.